Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,477 total articles
Advanced Drainage Systems (WMS) manufactures thermoplastic corrugated pipe and a suite of stormwater-management products. With a market cap near $10.7B, consistent free cash flow generation, and exposure to a growing stormwater and plastic-pipe market, the stock looks attractive at $139.16. This trade idea outlines an actionable long with entry at …
Dynatrace (DT) has been punished for decelerating ARR guidance and competitive headlines, but the company sits on healthy free cash flow, low leverage and a product well-aligned with rising AI agent complexity. This trade idea buys the dip with a mid-term horizon: entry $41.28, stop $38.00, target $50.00.
Talen Energy (TLN) looks like a pragmatic long: an accretive acquisition, meaningful interest-cost savings, and healthy free cash flow give a clear path to near-term upside. Enter at $410.00 with a $395 stop and a $460 target over a mid-term (45 trading day) horizon for a asymmetrical risk-reward trade.
Microsoft plunged sharply on renewed concerns around lower-margin businesses and AI competitive intensity. That drop creates a compelling mid-term trade: buy weakness around $380.42 with a $440 target and a $356 stop. Fundamentals - $2.8T market cap, $72.9B free cash flow, 23.5x earnings - still support upside if execution holds. Technicals show ov…
uniQure (QURE) ripped higher to $48.20 on 06/17/2026 after the market interpreted a recent FDA communication as more constructive for the AMT-130 Huntington's BLA pathway. Heavy volume, elevated short interest and a stretched technical picture create a trade that aims to capture momentum while respecting the very real regulatory and legal clearance…
Palantir is delivering extraordinary growth and cash generation, yet the market is pricing near-encyclopedic future success. This trade idea lays out a tactical short with a mid-term horizon, concrete entry/stop/target, and a roadmap of catalysts and risks that could push the stock materially lower or quickly reverse the trade.
Pfizer shares trade at ~$25.91 with a $147.5B market cap, a 6.6% dividend yield and an EV/EBITDA of 8.9. With positive GLP-1 data for berobenatide, solid free cash flow of ~$9.5B and a still-reasonable leverage profile, I see a clear path for a rebound into the low $30s over the next 180 trading days. This is an actionable long trade with defined e…
Devon Energy has fallen with the recent pullback in oil but still carries a strong 2026 outlook: 1.38 MMboe/d production, $4.9B capex and plans to return up to 70% of free cash flow to shareholders while retiring $1.25B of debt. Technicals show the stock trading just above a near-term support band around $42. The trade: buy at $42.50, stop $41.50, …
Verastem is a small-cap oncology developer trading at $4.17 with a $366M market cap. Positive trial signals and an extensive registration plan for its lead program support a long trade. High short interest, prior safety headlines and limited liquidity make this a high-risk, high-reward idea — enter carefully, use a hard stop and size accordingly.
Red Robin (RRGB) has been trading as a turnaround story for months. With a lean market cap (~$118M), an EV/EBITDA of roughly 5x, and a string of operational fixes — including a revamped royalty program and focused marketing — the risk-reward now favors a tactical long. I’m upgrading to a buy for a long-term trade with clear entry, stop, and target …
Intuitive Surgical (ISRG) is trading well below its 52-week highs after a large 2026 drawdown. The company's dominant da Vinci installed base, high-margin recurring parts and services (roughly 75% of revenue), and double-digit growth in systems and procedures argue for a recovery. This trade idea outlines a mid-term swing entry, exit, and risk plan…
Expedia Group generates meaningful free cash flow, trades at reasonable operating multiples and is benefiting from distribution partnerships and TravelTech recognition. At $240.72 the stock looks mispriced versus its cash generation and operational momentum. This trade idea outlines a long-term buy with concrete entry, stop and target levels and a …
Netflix trades near its 52-week low with a sub-30 RSI, strong free cash flow and a reasonable P/E. Recent M&A misses and headline risk pushed the stock lower; that pullback creates an asymmetric trade where upside to $110 outpaces a calibrated downside to $71. This is a disciplined long trade for investors willing to hold a position for up to 180 t…
Redwire (RDW) is a mission-critical supplier for space infrastructure. Recent market flow and reported contract momentum give the stock a tactical lift after a volatile two-week stretch. The setup favors a mid-term long: modest entry, clear stop, and a realistic upside toward $20 if backlog converts and the sector rotation continues.
Norwegian Cruise Line (NCLH) remains under pressure after a guidance cut and several legal probes, but valuation, improving technicals, and clear operational fixes make a measured long the highest-probability trade over the next 45 trading days. Entry $20.40, stop $18.00, target $24.00.
Waste Management (WM) is not a moonshot. At $217.74 it trades at roughly 31x earnings with $3.3B of free cash flow and a recent $3B buyback program. For investors content with steady cash returns and limited upside, a disciplined long trade to $245 over the next 6 months with a tight stop makes sense — reward is modest, risk is manageable if levera…
SoFi (SOFI) is trading well below prior highs despite clear topline momentum, improving profitability metrics and accelerating product-led cross-sell. The market is pricing in disappointment; short interest and elevated short volume underscore skepticism. For disciplined traders, a mid-term long with a defined stop captures asymmetric upside if SoF…
Atlassian (TEAM) has the ingredients of a compounding SaaS business — high free cash flow, sticky products (Jira, Confluence, JSM), and renewed sector sentiment around AI workloads. The stock trades at about $87 with a market cap near $22.1B and a free cash flow yield north of 5% today, supporting a long-term trade. This note lays out an actionable…
Intuitive Surgical (ISRG) has pulled back roughly 30% from early-2026 highs, compressing a high-quality recurring-revenue franchise into a lower entry point. Valuation still looks full at ~50x EPS, but the installed base expansion, 75% recurring revenue mix, and accelerating procedures give the stock room to re-rate. This trade targets a patient lo…
L3Harris ($LHX) surged on fresh program-related headlines tied to 'Axyv' that materially alter near-term revenue and margin visibility. The company still trades at a premium multiple, but stronger FCF, a healthy balance sheet, and favorable macro catalysts (defense spending, space commercialization) make a mid-term swing buy. Entry, stop, and targe…
Rubrik reported a surprise profit in the last quarter, raised fiscal 2027 guidance for revenue and EPS, and is generating free cash flow while trading well below its 52-week high. The market has punished the name indiscriminately during the cybersecurity sell-off; we see room for a mid-term rebound into $85 with a disciplined stop below $62.
United Fire Group (UFCS) looks like a pragmatic value recovery. The stock trades at depressed multiples (P/E ~9.5, P/B ~1.3) while free cash flow and a beefed-up buyback program create a margin of safety. This trade targets a mid-term rebound into the mid-$50s, with a clear stop below recent support and thesis-driven catalysts.
Microsoft's core growth drivers - Intelligent Cloud, Office ecosystem monetization and enterprise AI adoption - remain intact despite questions around OpenAI exclusivity. Valuation at roughly $2.86T and a PE near 23x leaves room for upside if AI-driven ARR re-acceleration continues. This trade idea outlines a long trade with a clear entry, stop and…
Iovance Biotherapeutics has shifted from pure pipeline story to commercial-stage growth after Amtagvi (lifileucel) uptake produced high-single-digit to double-digit revenue expansion. The stock at $4.105 is priced for a binary outcome; we lay out a long trade that leans on accelerating revenue, upcoming clinical/regulatory catalysts, and improving …
Viant (DSP) pulled back from recent highs but still shows improving fundamentals: Q4 2025 revenue of $110M (+22%) and expanding non-GAAP net income to $19M. Technicals are neutral-to-bearish short term, creating a lower-risk entry near $10.95. We maintain a Buy rating with a mid-term target of $13.00 and a clear stop at $9.25.
